Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the efficacy of Lyophilized amniotic fluid as compared to the Saline Injection, placebo control in the treatment of moderate osteoarthritis of the knee.
Approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, Saline Placebo and 4ml 2x). The estimated enrollment period is 6 months. Each subject will receive 1 injection and be evaluated for efficacy and safety during a 6 month observation period. The study is expected to be completed within 12 months, inclusive of enrollment and follow-up for all subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 4mL amniotic fluid | Active Comparator | Amniotic Fluid: 4mL dose of amniotic fluid |
|
| 4mL2x amniotic fluid | Active Comparator | Amniotic Fluid: 4mL 2x dose of amniotic fluid |
|
| 4mL Saline Placebo | Placebo Comparator | Normal Saline |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amniotic Fluid | Other | Amniotic Fluid |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in Pain | The proportion of subjects who experience at least 20% improvement over baseline in Visual Analog Scale for Pain at 3 months in the Lyophilized amniotic fluid Injectable versus placebo-treated group. | 3 month |
| Measure | Description | Time Frame |
|---|---|---|
| Range of Motion | subjects who experience a level of improvement in function as assessed by range of motion at 3 months | 3 months |
| Knee Injury and Osteoarthritis Outcome Score | measurement to assess the patient's opinion about their knee and associated problems by looking at pain, functions of daily living, function in sports and recreation, knee related quality of life and other symptoms |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Mason, MD | Chief Medical Officer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Research Associates, Inc | Birmingham | Alabama | 35205 | United States | ||
| Southeastern Center for Clinical Trials |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, Saline Placebo and 4ml 2x).
Not provided
Not provided
Not provided
| Saline Placebo |
| Other |
Saline Placebo |
|
| 4weeks, 6weeks, 3 months, 16 weeks, 6 months |
| SF-12 Health Health Survey | patient-reported survey assessing patient health | 4weeks, 6weeks, 3 months, 16 weeks, 6 months |
| Activity of Daily Living Questionnaire | Changes in the subject's physical activity level | 4weeks, 6weeks, 3 months, 16 weeks, 6 months |
| Atlanta |
| Georgia |
| 30033 |
| United States |
| Weil Foot, Ankle and Orthopedic Institute | Des Plaines | Illinois | 60016 | United States |
| Hinsdale Orthopaedic Associates | Hinsdale | Illinois | 60521 | United States |
| D012216 |
| Rheumatic Diseases |